AbbVie Inc. / FutureGen Biopharmaceutical (Shanghai) Co. Ltd.

Inflammatory bowel disease (ulcerative colitis and Crohn's disease)

3.1M US cases/yr · $23.0B Global IBD market (2024) · $21B Humira (adalimumab) peak global sales (2022, pre-biosimilar) - benchmark for IBD franchise value

Disease Overview

Inflammatory bowel disease (IBD) comprises ulcerative colitis (UC) and Crohn's disease (CD), chronic relapsing immune-mediated conditions of the gastrointestinal tract. The CDC estimates approximately 3.1 million US adults living with diagnosed IBD (roughly 1.3% of US adults), split roughly evenly between UC and CD. Incidence has risen steadily over the past two decades, particularly in adolescent and young adult populations. Standard of care includes 5-aminosalicylates, corticosteroids, thiopurines, methotrexate, and increasingly advanced biologics: anti-TNF agents (Humira/adalimumab, Remicade/infliximab, Simponi/golimumab), anti-integrin (Entyvio/vedolizumab), anti-IL-12/23 (Stelara/ustekinumab), anti-IL-23 (Skyrizi/risankizumab, Omvoh/mirikizumab, Tremfya/guselkumab), and oral JAK inhibitors (Rinvoq/upadacitinib, Xeljanz/tofacitinib) plus S1P modulators (Zeposia/ozanimod, Velsipity/etrasimod). Despite this expanded armamentarium, approximately 30-50% of patients fail to achieve durable clinical remission on first or second advanced therapies, and many cycle through multiple mechanisms. The global IBD market exceeded $23 billion in 2024 and is projected to reach $30+ billion by 2030, with next-generation targets — TL1A, IL-23 selective agents, and oral small molecules — driving growth. TL1A (tumor necrosis factor-like ligand 1A, TNFSF15) has emerged as a validated novel target after encouraging Phase 2 data from Roivant/Pfizer's RVT-3101 (tulisokibart / TEV-48574).

Competitive Landscape

The TL1A class is IBD's most contested next-wave target. Merck paid $10.8 billion in April 2023 to acquire Prometheus Biosciences for tulisokibart (PRA-023 / MK-7240), a first-in-class humanized anti-TL1A monoclonal antibody that demonstrated positive Phase 2 ARTEMIS-UC and APOLLO-CD readouts. Roivant Sciences/Pfizer's RVT-3101 (afimkibart / PF-06480605, now TEV-48574 after the Teva license) is a competing anti-TL1A with Phase 2b data in UC showing meaningful clinical remission rates; Teva paid $500M upfront in 2023 for co-development rights. Sanofi acquired TL1A developer Teva's program stake and has its own TL1A (SAR443122) in early development. Beyond TL1A, the IBD landscape is dense with approved biologics — Humira (adalimumab), Remicade (infliximab), Entyvio (vedolizumab), Stelara (ustekinumab), Skyrizi (risankizumab), Omvoh (mirikizumab), Tremfya (guselkumab), Rinvoq (upadacitinib), Xeljanz (tofacitinib), Zeposia (ozanimod), and Velsipity (etrasimod). AbbVie already owns Humira, Skyrizi, and Rinvoq, making FG-M701 a defensive complement to its immunology franchise as Humira erodes under biosimilar competition. FG-M701's differentiation rests on antibody engineering for longer half-life and less frequent dosing.